1 Louisiana State University, Section of Pulmonary/Critical Care Medicine, New Orleans, Louisiana.
2 University of Washington, Division of Pulmonary/Critical Care Medicine, Seattle, Washington.
Ann Am Thorac Soc. 2017 Sep;14(9):1443-1449. doi: 10.1513/AnnalsATS.201611-906OC.
Short-term follow-up in the Fluid and Catheter Treatment Trial (FACTT) suggested differential mortality by race with conservative fluid management, but no significant interaction.
In a post hoc analysis of FACTT including 1-year follow-up, we sought to estimate long-term mortality by race and test for an interaction between fluids and race.
We performed a post hoc analysis of FACTT and the Economic Analysis of Pulmonary Artery Catheters (EAPAC) study (which included 655 of the 1,000 FACTT patients with near-complete 1-year follow up). We fit a multistate Markov model to estimate 1-year mortality for all non-Hispanic black and white randomized FACTT subjects. The model estimated the distribution of time from randomization to hospital discharge or hospital death (available on all patients) and estimated the distribution of time from hospital discharge to death using data on patients after hospital discharge for patients in EAPAC. The 1-year mortality was found by combining these estimates.
Non-Hispanic black (n = 217, 25%) or white identified subjects (n = 641, 75%) were included. There was a significant interaction between race and fluid treatment (P = 0.012). One-year mortality was lower for black subjects assigned to conservative fluids (38 vs. 54%; mean mortality difference, 16%; 95% confidence interval, 2-30%; P = 0.027 between conservative and liberal). Conversely, 1-year mortality for white subjects was 35% versus 30% for conservative versus liberal arms (mean mortality difference, -4.8%; 95% confidence interval, -13% to 3%; P = 0.23).
In our cohort, conservative fluid management may have improved 1-year mortality for non-Hispanic black patients with ARDS. However, we found no long-term benefit of conservative fluid management in white subjects.
短期随访的液体和导管治疗试验(FACTT)表明,在采用保守液体管理的情况下,不同种族的死亡率存在差异,但没有显著的交互作用。
在 FACTT 的事后分析中,包括 1 年的随访,我们试图根据种族估计长期死亡率,并检验液体与种族之间的相互作用。
我们对 FACTT 和肺动脉导管经济学分析(EAPAC)研究进行了事后分析(其中包括 1000 名 FACTT 患者中的 655 名,他们几乎完全有 1 年的随访)。我们使用多状态马尔可夫模型来估计所有非西班牙裔黑人(n=217,25%)和白人(n=641,75%)随机 FACTT 受试者的 1 年死亡率。该模型估计了从随机分组到医院出院或医院死亡的时间分布(所有患者均可获得),并使用 EAPAC 中出院后患者的数据来估计从医院出院到死亡的时间分布。将这些估计值结合起来,得到 1 年的死亡率。
纳入了非西班牙裔黑人(n=217,25%)或白人(n=641,75%)的识别患者。种族和液体治疗之间存在显著的交互作用(P=0.012)。保守液体治疗组的黑人患者 1 年死亡率较低(38%比 54%;平均死亡率差异为 16%,95%置信区间为 2-30%;保守与宽松治疗之间的 P=0.027)。相反,白人患者保守组的 1 年死亡率为 35%,宽松组为 30%(保守与宽松治疗之间的平均死亡率差异为-4.8%,95%置信区间为-13%至 3%;P=0.23)。
在我们的队列中,保守液体管理可能改善了 ARDS 非西班牙裔黑人患者的 1 年死亡率。然而,我们没有发现保守液体管理对白人患者有长期获益。